Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | PGD | P52209 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27449129 | 0.87 | HIF1A (0.36) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL11124880 | 0.86 | MAPT (0.33) | TSHRTDP1MAPTALDH1A1 | |
| SCHEMBL8988942 | 0.80 | TSHR (0.47) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL15934939 | 0.80 | USP2 (0.40) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10782810 | 0.80 | TSHR (0.50) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL9736110 | 0.78 | TSHR (0.36) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL8564505 | 0.77 | ADH1B (0.38) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10525623 | 0.76 | TSHR (0.42) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL2230506 | 0.75 | TSHR (0.46) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL7647831 | 0.75 | TSHR (0.33) | TSHRTDP1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | IMMUNOMEDICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| CN-117138060-A | New adjuvant use of antibody-drug conjugates | 免疫医疗公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210275682-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | IMMUNOMEDICS, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-2981281-B1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190142939-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142939-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10245321-B2 | Combination therapy for inducing immune response to disease | IBC PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10245321-B2 | Combination therapy for inducing immune response to disease | IBC PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10131712-B2 | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors | IBC PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2014163684-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014124227-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | IMMUNOMEDICS, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140219956-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | IMMUNOMEDICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140219956-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | IMMUNOMEDICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140099254-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| CN-1116267-C | Process for producing branched aldehydes | KURARAY CO (JP) | 2003-07-30 | — | — | CN | disclosed |
| CN-1197788-A | Process for producing branched aldehydes | KURARAY CO (JP) | 1998-11-04 | — | — | CN | disclosed |
| US-4176190-A | Diuretic and saliuretic sulphamoylbenzoic acids | CIBA-GEIGY CORPORATION (US) | 1979-11-27 | — | — | US | disclosed |
| US-4016283-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
| US-3984436-A | BLOCKERS OF ADRENERGIC B-RECEPTORS | CIBA-GEIGY CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245321-B2 | Combination therapy for inducing immune response to disease | ICOS, IFNG, CD274 | TSHR 981/4885TDP1 324/4885CHRM2 1092/4885 |
| US-20140219956-A1 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER | P2RX2, ENTPD1, P2RX1 | TSHR 1173/4885TDP1 1499/4885CHRM2 3248/4885 |
| US-20190142939-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | ICOS, IFNG, CD274 | TSHR 981/4885TDP1 324/4885CHRM2 1092/4885 |
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD8 | TSHR 2234/4885TDP1 726/4885CHRM2 1622/4885 |
| US-20140099254-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | CD274, IFNG, CD14 | TSHR 1981/4885TDP1 2908/4885CHRM2 4581/4885 |
| US-20210275682-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD8 | TSHR 2234/4885TDP1 726/4885CHRM2 1622/4885 |
| US-10131712-B2 | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors | CD274, IFNG, PDCD1 | TSHR 619/4885TDP1 486/4885CHRM2 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.